Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002101 · ClinicalTrials.gov registry record · Phase 3
A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
A Phase 3 study, sponsored by Pharmacia.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
NCT00002101 is a Phase 3 study that has completed, run by Pharmacia. The registered enrollment target is 450 participants.
The verdict
NCT00002101, a Phase 3 study, has completed, sponsored by Pharmacia.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
Study Summary
To compare the efficacy of clarithromycin/ethambutol with placebo or with rifabutin at two different doses in reducing colony-forming units (CFUs) by 2 or more logarithms in patients with Mycobacterium avium Complex bacteremia and maintaining this response until 16 weeks post-randomization. To assess survival and comparative tolerability among the three treatment regimens.
Interventions
- DRUG Rifabutin
- DRUG Clarithromycin
- DRUG Ethambutol hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002101
The ClinicalTrials.gov registry entry for NCT00002101 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacia, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifabutin is the first listed.
NCT00002101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002101 about?
NCT00002101 is a clinical study titled "A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo". To compare the efficacy of clarithromycin/ethambutol with placebo or with rifabutin at two different doses in reducing colony-forming units (CFUs) by 2 or more logarithms in patients with Mycobacterium avium Complex bacteremia and maintaining this response until 16 weeks post-randomization. To asses...
What is the current status of trial NCT00002101?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants.
What interventions are being tested in trial NCT00002101?
The interventions under investigation include: Rifabutin (DRUG), Clarithromycin (DRUG), Ethambutol hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002101?
This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.